Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Virology, and Neurodegeneration Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NEDD4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NEDD4 Wild-Type & Catalytic Mutant (C867S) Recombinant Proteins High purity (>95%), Endotoxin controlled. Sequence Verified by MS. Suitable for ubiquitination assays. |
View NEDD4 Products |
| Gene Delivery | NEDD4 Promise-ORF / Lentivirus Full-length human NEDD4 ORF for stable cell line generation and overexpression validation. |
View NEDD4 Products |
| Benchmark Ab | Anti-NEDD4 Recombinant Antibody High-affinity positive control for Western Blot, IP, and ELISA validation. |
View NEDD4 Products |
| Validator | NEDD4 siRNA Set Target-specific knockdown pool for functional validation and phenotypic assays. |
View NEDD4 Products |
| Related Target A | PTEN Primary tumor suppressor substrate of NEDD4; critical for monitoring ubiquitination and degradation kinetics. |
View PTEN Products |
| Related Target B | NEDD4L (NEDD4-2) Closest subfamily homolog; essential counter-screening target to ensure drug selectivity and avoid off-target renal toxicity. |
View NEDD4L Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| HECT Domain Selectivity (off-target screening against NEDD4L/ITCH) | Highly purified recombinant HECT domain panels available with verified theoretical MW and sequence integrity. |
| Assay False Positives (distinguishing true ligase inhibition from aggregation) | Catalytically inactive mutant NEDD4 (C867S) provided as a structural negative control for in vitro assays. |
| Cell-Based Target Engagement | High-titer Lentiviral vectors enabling uniform, stable expression of NEDD4 in target cancer cell lines. |
| In Vitro Ubiquitination Reconstitution | Low-endotoxin, high-purity WT NEDD4 protein optimized for compatibility with enzyme cascade reactions. |
Live NEDD4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the E3 ubiquitin ligase NEDD4 (Neural precursor cell expressed developmentally down-regulated protein 4) has emerged as a high-potential frontier in oncology, antiviral therapy, and neurodegenerative disorders. As the founding member of the HECT-type E3 ligase family, NEDD4 regulates key physiological processes by ubiquitinating substrates such as PTEN, AKT, and various viral late-domain proteins.
The race for NEDD4 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum proteasome inhibitors to targeted small-molecule inhibitors and PROTACs (Proteolysis Targeting Chimeras). As first-generation small-molecule inhibitors targeting the catalytic HECT domain reach preclinical validation, the next wave of R&D is targeting the distinct WW domains of NEDD4 to disrupt specific protein-protein interactions, offering superior selectivity over structural homologs.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (HECT Inhibitors) | Preclinical Biotech, Academic Consortia | PTEN-deficient Solid Tumors, Glioma | Selectivity Assay (Need Mutant vs WT Proteins and NEDD4L panel) |
| PROTACs (NEDD4 Degraders) | Targeted Protein Degradation (TPD) Pioneers | Prostate Cancer, Hematological Malignancies | Ubiquitination Kinetics (Need High-Purity WT Protein & Substrates like PTEN) |
| Antiviral Small Molecules | Infectious Disease Research Institutes | Enveloped Viral Infections (Ebola, Marburg) | PPxY Motif Binding Assays (Need WW-domain fragments and Lentivirus) |